Phase 1 Acromegaly Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1
Study of MAR002 in Healthy Men
Acromegaly
Marea Therapeutics45 enrolled1 locationNCT07195175
Not Yet Recruiting
Phase 1
A Phase 1, Single-Dose, Open-Label, Randomized, Three-Period, Two-Sequence, Crossover Study to Evaluate the Relative Bioavailability of Paltusotine Low Drug Load (LDL) Tablets 60 mg (2 × 30 mg LDL tablet) and High Drug Load (HDL) Tablet 60 mg (1 × 60 mg HDL tablet) in Healthy Volunteers.
Carcinoid SyndromeAcromegaly
Crinetics Pharmaceuticals, Inc20 enrolled1 locationACTRN12625001148460
Completed
Phase 1
Phase I, open-label, sequential-group, three-cohort study to evaluate the pharmacokinetic profile, the safety and the tolerability of a single injection of lanreotide Extended-Release Formulation (ERF) at doses of 120 mg and 240 mg in healthy volunteers
Acromegaly
Ascil Australia36 enrolled1 locationACTRN12624000390583
Completed
Phase 1
A Phase 1, Open-label, Multi-Period, Single Sequence Study to Evaluate the Relative Bioavailability, Performance, and Safety of Two Solid Oral Doses (Paltusotine Tablets) in Healthy Volunteers
Acromegaly
Crinetics Australia Pty Ltd14 enrolled1 locationACTRN12622000704796
Completed
Phase 1
A Phase 1, Open Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of Two Paltusotine Tablet Strengths in Healthy Volunteers
Acromegaly
Crinetics Australia Pty Ltd12 enrolled1 locationACTRN12622000491763
Recruiting
Phase 1
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers
AcromegalyNeuroendocrine Tumours
Ascil Australia Pty LTD16 enrolled1 locationACTRN12620001261909
Completed
Phase 1
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteers
AcromegalyNeuroendocrine Tumours
Ascil Australia Pty Ltd8 enrolled1 locationACTRN12620000108910
Completed
Phase 1
A Phase 1, Multi-Cohort, Single Dose Study to Assess The Relative Bioavailability, Performance, and Safety of Two Novel Formulations of CRN00808
Acromegaly
Crinetics Australia Pty Ltd60 enrolled1 locationACTRN12619001562167
Completed
Phase 1
An open label, single cohort, randomized, 4-period crossover Phase 1 study to determine the effect of meal timing relative to CRN00808 administration on the safety and pharmacokinetics of CRN00808 in healthy volunteers
Acromegaly
Crinetics Australia Pty Ltd12 enrolled1 locationACTRN12618001646235
Completed
Phase 1
A Randomised, Placebo Controlled, Double-Blind, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1103 in Healthy Adult Male Subjects
ATL1103 is being developed as a potential treatment for diseases of excessive growth hormone and insulin-like growth hormone (IGF)-I action, including the condition acromegaly.
Antisense Therapeutics Limited36 enrolled1 locationACTRN12611000854932